These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 24460647)

  • 61. Managing and preventing atypical hemolytic uremic syndrome recurrence after kidney transplantation.
    Noris M; Remuzzi G
    Curr Opin Nephrol Hypertens; 2013 Nov; 22(6):704-12. PubMed ID: 24076560
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Preformed complement-activating low-level donor-specific antibody predicts early antibody-mediated rejection in renal allografts.
    Lawrence C; Willicombe M; Brookes PA; Santos-Nunez E; Bajaj R; Cook T; Roufosse C; Taube D; Warrens AN
    Transplantation; 2013 Jan; 95(2):341-6. PubMed ID: 23197178
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Complement factor H-antibody-associated hemolytic uremic syndrome: pathogenesis, clinical presentation, and treatment.
    Hofer J; Giner T; Józsi M
    Semin Thromb Hemost; 2014 Jun; 40(4):431-43. PubMed ID: 24799303
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Relevance of different antibody detection methods for the prediction of antibody-mediated rejection and deceased-donor kidney allograft survival.
    Vlad G; Ho EK; Vasilescu ER; Colovai AI; Stokes MB; Markowitz GS; D'Agati VD; Cohen DJ; Ratner LE; Suciu-Foca N
    Hum Immunol; 2009 Aug; 70(8):589-94. PubMed ID: 19375470
    [TBL] [Abstract][Full Text] [Related]  

  • 65. HLA-C antibodies are associated with irreversible rejection in kidney transplantation: Shared molecular eplets characterization.
    Bosch A; Llorente S; Eguia J; Mrowiec A; Boix F; López-Hernández R; Campillo JA; Salgado G; Moya-Quiles MR; Minguela A; Jimeno L; Alvarez-López MR; Muro M
    Hum Immunol; 2014 Apr; 75(4):338-41. PubMed ID: 24486575
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Clinical-pathological correlations in post-transplant thrombotic microangiopathy.
    Broecker V; Bardsley V; Torpey N; Perera R; Montero R; Dorling A; Bentall A; Neil D; Willicombe M; Berry M; Roufosse C
    Histopathology; 2019 Jul; 75(1):88-103. PubMed ID: 30851188
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Posttransplant recurrence of atypical hemolytic uremic syndrome.
    Valoti E; Alberti M; Noris M
    J Nephrol; 2012; 25(6):911-7. PubMed ID: 22760880
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Donor-specific antibodies against HLA, MICA, and GSTT1 in patients with allograft rejection and C4d deposition in renal biopsies.
    Alvarez-Márquez A; Aguilera I; Gentil MA; Caro JL; Bernal G; Fernández Alonso J; Acevedo MJ; Cabello V; Wichmann I; Gonzalez-Escribano MF; Núñez-Roldán A
    Transplantation; 2009 Jan; 87(1):94-9. PubMed ID: 19136897
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Successful kidney transplant with eculizumab, thymoglobulin and belatacept therapy in a highly-sensitised patient with atypical haemolytic uraemic syndrome due to factor H mutation.
    Nieto-Ríos JF; Zuluaga-Quintero M; Bello-Márquez DC; Aristizabal-Alzate A; Ocampo-Kohn C; Serna-Higuita LM; Arias L; Zuluaga-Valencia G
    Nefrologia (Engl Ed); 2018; 38(4):433-437. PubMed ID: 29778558
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Complement-binding anti-HLA antibodies and kidney-allograft survival.
    Loupy A; Lefaucheur C; Vernerey D; Prugger C; Duong van Huyen JP; Mooney N; Suberbielle C; Frémeaux-Bacchi V; Méjean A; Desgrandchamps F; Anglicheau D; Nochy D; Charron D; Empana JP; Delahousse M; Legendre C; Glotz D; Hill GS; Zeevi A; Jouven X
    N Engl J Med; 2013 Sep; 369(13):1215-26. PubMed ID: 24066742
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A case of late onset cyclosporine-induced hemolytic uremic syndrome resulting in renal graft loss.
    Katafuchi R; Saito S; Ikeda K; Hirano T; Yanase T; Nakashima K; Fujimi S
    Clin Transplant; 1999; 13 Suppl 1():54-8. PubMed ID: 10751058
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Low median fluorescence intensity could be a nonsafety concept of immunologic risk evaluation in patients with shared molecular eplets in kidney transplantation.
    Bosch A; Llorente S; Diaz JA; Salgado G; López M; Boix F; López-Hernández R; González-Soriano MJ; Campillo JA; Moya-Quiles MR; Perez-Lopez N; Minguela A; Jimeno L; Alvarez-López MR; Muro M
    Hum Immunol; 2012 May; 73(5):522-5. PubMed ID: 22425738
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Donor specific antibodies before and after kidney transplant: the University of Colorado Experience.
    Cooper JE; Gralla J; Adebiyi O; Wiseman AC; Chan L
    Clin Transpl; 2013; ():407-12. PubMed ID: 25095536
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Recurrent ocular involvement in pediatric atypical hemolytic uremic syndrome.
    Zheng X; Gorovoy IR; Mao J; Jin J; Chen X; Cui QN
    J Pediatr Ophthalmol Strabismus; 2014 Oct; 51 Online():e62-5. PubMed ID: 25347082
    [TBL] [Abstract][Full Text] [Related]  

  • 75. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document.
    Campistol JM; Arias M; Ariceta G; Blasco M; Espinosa M; Grinyó JM; Praga M; Torra R; Vilalta R; Rodríguez de Córdoba S
    Nefrologia; 2013 Jan; 33(1):27-45. PubMed ID: 23364625
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Living-donor kidney transplantation for atypical haemolytic uremic syndrome with pre-emptive eculizumab use.
    Parikova A; Fronek JP; Viklicky O
    Transpl Int; 2015 Mar; 28(3):366-9. PubMed ID: 25256057
    [No Abstract]   [Full Text] [Related]  

  • 77. Ocular involvement in atypical haemolytic uraemic syndrome.
    Sampedro López A; Domínguez Moro B; Baltar Martin JM; Garcia Monteavaro C; Barbón García JJ
    Arch Soc Esp Oftalmol; 2017 Dec; 92(12):594-597. PubMed ID: 28347544
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Atypical Hemolytic-Uremic Syndrome: A Clinical Review.
    Nayer A; Asif A
    Am J Ther; 2016; 23(1):e151-8. PubMed ID: 24681522
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Recurrent ocular involvement in pediatric atypical hemolytic uremic syndrome.
    Zheng X; Gorovoy IR; Mao J; Jin J; Chen X; Cui QN
    J Pediatr Ophthalmol Strabismus; 2014 Oct; 51():e62-5. PubMed ID: 25608228
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Complement inhibition as potential new therapy for antibody-mediated rejection.
    Eskandary F; Wahrmann M; Mühlbacher J; Böhmig GA
    Transpl Int; 2016 Apr; 29(4):392-402. PubMed ID: 26474721
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.